• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

    5/8/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGO alert in real time by email

    CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025.

    First Quarter 2025 Financial Results Summary:

    • Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of:
      • Net revenue from Advanced Wound Care products of $79.9 million, a decrease of 23% from the first quarter of 2024.
      • Net revenue from Surgical & Sports Medicine products of $6.8 million, an increase of 11% from the first quarter of 2024.
    • Net loss of $18.8 million for the first quarter of 2025, compared to a net loss of $2.1 million for the first quarter of 2024, an increase in net loss of $16.7 million.
    • Adjusted net loss of $13.4 million for the first quarter of 2025, compared to an adjusted net loss of $1.4 million for the first quarter of 2024, an increase in adjusted net loss of $12.0 million.
    • Adjusted EBITDA loss of $12.5 million for the first quarter of 2025, compared to Adjusted EBITDA income of $2.6 million for the first quarter of 2024, a decrease of $15.1 million.

    "I'm proud of the team's continued dedication to our customers and their patients in this challenging market. We managed the anticipated disruption well and I'm confident in our ability to execute on our commercial strategy for the remainder of the year," said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. "With our strong brand equity, diverse portfolio and deep customer relationships, we remain well-positioned to navigate the evolving reimbursement landscape."

    Mr. Gillheeney, Sr. continued: "We continue to progress the ReNu development plan with all patients expected to complete the second phase 3 study by the end of the second quarter and remain on track to submit the BLA by the end of 2025."

    First Quarter 2025 Financial Results:

      Three Months Ended March 31,  Change 
      2025  2024  $  % 
      (in thousands, except for percentages) 
    Advanced Wound Care $79,927  $103,864  $(23,937)  (23%)
    Surgical & Sports Medicine  6,766   6,112   654   11%
    Net revenue $86,693  $109,976  $(23,283)  (21%)



    Net revenue for the first quarter of 2025 was $86.7 million, compared to $110.0 million for the first quarter of 2024, a decrease of $23.3 million, or 21%. The decrease in net revenue was driven by a decrease of $23.9 million, or 23%, in net revenue for Advanced Wound Care products partially offset by an increase of $0.7 million, or 11%, in net revenue for Surgical & Sports Medicine products.

    Gross profit for the first quarter of 2025 was $63.0 million, or 73% of net revenue, compared to $81.3 million, or 74% of net revenue for the first quarter of 2024, a decrease of $18.3 million, or 23%.

    Operating expenses for the first quarter of 2025 were $89.7 million compared to $85.1 million for the first quarter of 2024, an increase of $4.6 million, or 5%. R&D expense was $10.6 million for the first quarter of 2025, compared to $12.8 million for the first quarter of 2024, a decrease of $2.2 million, or 17%. Selling, general and administrative expenses were $72.5 million for the first quarter of 2025, compared to $72.3 million for the first quarter of 2024, an increase of $0.2 million, or less than 1%. For the three months ended March 31, 2025, the Company recorded write down expenses of $6.6 million.

    Operating loss for the first quarter of 2025 was $26.7 million, compared to an operating loss of $3.9 million for the first quarter of 2024, an increase in operating loss of $22.9 million.

    Total other (income) expense, net, for the first quarter of 2025 was $(1.0) million income, compared to $0.5 million expense for the first quarter of 2024, a change of $1.5 million.

    Net loss for the first quarter of 2025 was $18.8 million, or $(0.17) per share, compared to net loss of $2.1 million, or $(0.02) per share, for the first quarter of 2024, an increase in net loss of $16.7 million, or $(0.15) per share.

    Adjusted net loss was $13.4 million for the first quarter of 2025, compared to adjusted net loss of $1.4 million for the first quarter of 2024, an increase in adjusted net loss of $12.0 million.

    Adjusted EBITDA loss was $(12.5) million for the first quarter of 2025, compared to Adjusted EBITDA income of $2.6 million for the first quarter of 2024, a change of $15.1 million.

    Non-GAAP operating loss was $19.3 million for the first quarter of 2025, compared to non-GAAP operating loss of $3.0 million for the first quarter of 2024, a change of $16.4 million.

    As of March 31, 2025, the Company had $110.5 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $136.2 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2024.

    Fiscal Year 2025 Guidance:

    For the year ending December 31, 2025, the Company is reaffirming its prior revenue guidance and updating its profitability guidance and expects:

    • Net revenue between $480.0 million and $535.0 million, representing a year-over-year change in the range of a roughly flat to an increase of 11%, as compared to net revenue of $482.0 million for the year ended December 31, 2024.
      • The 2025 net revenue guidance range assumes:
        • Net revenue from Advanced Wound Care products between $450.0 million and $500.0 million, a decrease of 1% to an increase of 10% year-over-year as compared to net revenue of $453.6 million for the year ended December 31, 2024.
        • Net revenue from Surgical & Sports Medicine products between $30.0 million and $35.0 million, an increase of 6% to 23% year-over-year as compared to net revenue of $28.4 million for the year ended December 31, 2024.
    • Net income between $4.7 million and $34.0 million and adjusted net income between $15.3 million and $44.6 million.
    • EBITDA between $20.0 million and $59.6 million and Adjusted EBITDA between $43.6 million and $83.2 million.

    First Quarter Earnings Conference Call:

    Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here or access the teleconference here. The live webcast can also be accessed via the company's website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.



    ORGANOGENESIS HOLDINGS INC.


    UNAUDITED CONSOLIDATED BALANCE SHEETS

    (amounts in thousands, except share and per share data)

      March 31,  December 31, 
      2025  2024 
    Assets      
    Current assets:      
    Cash and cash equivalents $109,965  $135,571 
    Restricted cash  569   580 
    Accounts receivable, net  103,320   109,861 
    Inventories, net  29,338   26,219 
    Asset held for sale (Note 6)  7,033   — 
    Prepaid expenses and other current assets  17,935   13,710 
    Total current assets  268,160   285,941 
    Property and equipment, net  75,518   89,128 
    Intangible assets, net  11,626   12,468 
    Goodwill  28,772   28,772 
    Operating lease right-of-use assets, net  36,756   37,110 
    Deferred tax asset, net  40,728   39,462 
    Other assets  5,834   5,005 
    Total assets $467,394  $497,886 
    Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity      
    Current liabilities:      
    Current portion of finance lease obligations $1,193  $1,170 
    Current portion of operating lease obligations - related party  3,712   3,671 
    Current portion of operating lease obligations  4,353   4,272 
    Accounts payable  24,660   28,911 
    Accrued expenses and other current liabilities  31,135   39,453 
    Total current liabilities  65,053   77,477 
    Finance lease obligations, net of current portion  411   718 
    Operating lease obligations, net of current portion - related party  7,339   8,283 
    Operating lease obligations, net of current portion  25,625   25,198 
    Other liabilities  897   894 
    Total liabilities  99,325   112,570 
    Commitments and contingencies (Note 15)      
           
    Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding at March 31, 2025 and December 31, 2024; liquidation preference of $134,014 and $131,387 at March 31, 2025 and December 31, 2024, respectively.  125,167   122,419 
           
    Stockholders' equity:      
    Preferred stock, $0.0001 par value; 870,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; none issued or outstanding  —   — 
    Common stock, $0.0001 par value; 400,000,000 shares authorized; 127,582,084 and 126,458,784 shares issued; 126,853,536 and 125,730,236 shares outstanding at March 31, 2025 and December 31, 2024, respectively.  13   13 
    Additional paid-in capital  301,842   302,994 
    Accumulated deficit  (58,953)  (40,110)
    Total stockholders' equity  242,902   262,897 
    Total liabilities, redeemable convertible preferred stock, and stockholders' equity $467,394  $497,886 



    ORGANOGENESIS HOLDINGS INC.

    UNAUDITED
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (amounts in thousands, except share and per share data)

      Three Months Ended

    March 31,
     
      2025  2024 
    Net revenue $86,693  $109,976 
    Cost of goods sold  23,723   28,696 
    Gross profit  62,970   81,280 
    Operating expenses:      
    Selling, general and administrative  72,509   72,322 
    Research and development  10,640   12,810 
    Write-down to fair value for asset held for sale  6,567   — 
    Total operating expenses  89,716   85,132 
    Loss from operations  (26,746)  (3,852)
    Other expense, net:      
    Interest income (expense), net  961   (514)
    Other income, net  2   23 
    Total other income (expense), net  963   (491)
    Net loss before income taxes  (25,783)  (4,343)
    Income tax benefit  6,940   2,243 
    Net loss and comprehensive loss  (18,843)  (2,100)
    Accretion of redeemable convertible preferred stock to redemption value  (121)  — 
    Cumulative dividend on redeemable convertible preferred stock  (2,627)  — 
    Net loss attributable to common stockholders $(21,591) $(2,100)
           
    Net loss, per share:      
    Basic and diluted $(0.17) $(0.02)
    Weighted-average common shares outstanding      
    Basic and diluted  126,295,642   131,861,772 



    ORGANOGENESIS HOLDINGS INC.

    UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS


    (amounts in thousands, except share and per share data)

      Three Months Ended

    March 31,
     
      2025  2024 
    Cash flows from operating activities:      
    Net loss $(18,843) $(2,100)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Depreciation and amortization  3,444   3,072 
    Amortization of intangible assets  842   901 
    Reduction in the carrying value of right-of-use assets  1,997   2,203 
    Non-cash interest expense  69   105 
    Deferred interest expense  —   122 
    Deferred tax benefit  (1,266)  — 
    Provision recorded for credit losses  873   968 
    Loss on disposal of property and equipment  19   347 
    Adjustment for excess and obsolete inventories  3,709   2,515 
    Stock-based compensation  3,367   2,407 
    Write-down to fair value for asset held for sale  6,567   — 
    Changes in operating assets and liabilities:      
    Accounts receivable  5,668   (15,117)
    Inventories  (8,732)  (4,670)
    Prepaid expenses and other current assets and other assets  (5,123)  (4,315)
    Operating leases  (2,037)  (2,199)
    Accounts payable  (2,496)  (4,391)
    Accrued expenses and other liabilities  (7,993)  9,990 
    Net cash used in operating activities  (19,935)  (10,162)
    Cash flows from investing activities:      
    Purchases of property and equipment  (3,626)  (2,222)
    Net cash used in investing activities  (3,626)  (2,222)
    Cash flows from financing activities:      
    Payments of term loan under the 2021 Credit Agreement  —   (1,406)
    Payments of withholding taxes in connection with RSUs vesting  (1,796)  (1,120)
    Proceeds from the exercise of stock options  25   180 
    Principal repayments of finance lease obligations  (285)  (262)
    Net cash used in financing activities  (2,056)  (2,608)
    Change in cash, cash equivalents and restricted cash  (25,617)  (14,992)
    Cash, cash equivalents, and restricted cash, beginning of period  136,151   104,338 
    Cash, cash equivalents, and restricted cash, end of period $110,534  $89,346 
    Supplemental disclosure of cash flow information:      
    Cash paid for interest $—  $1,375 
    Cash paid for income taxes $150  $35 
    Supplemental disclosure of non-cash investing and financing activities:      
    Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock $2,748  $— 
    Purchases of property and equipment included in accounts payable and accrued expenses $172  $786 
    Right-of-use assets obtained through operating lease obligations $1,642  $701 



    Non-GAAP Financial Measures

    Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and adjusted net income (loss) to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA, adjusted net income (loss) and non-GAAP operating income (loss) provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

    Adjusted EBITDA

    Adjusted EBITDA consists of GAAP net loss excluding: (i) interest (income) expense, net, (ii) income tax (benefit), (iii) depreciation and amortization, (iv) amortization of intangible assets, (v) stock-based compensation expense, and (vi) additional infrequently occurring adjustments described in more detail below.

    The following table presents a reconciliation of GAAP net loss to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:

      Three Months Ended March 31, 
      2025  2024 
      (Unaudited, in thousands) 
    Net loss $(18,843) $(2,100)
    Interest (income) expense, net  (961)  514 
    Income tax benefit  (6,940)  (2,243)
    Depreciation and amortization  3,444   3,072 
    Amortization of intangible assets  842   901 
    EBITDA  (22,458)  144 
    Stock-based compensation expense  3,367   2,407 
    Write-down to fair value for asset held for sale1  6,567  — 
    Adjusted EBITDA $(12,524) $2,551 

    (1)   Amount reflects the fair value adjustment of a purchased building classified as held for sale.

    Adjusted Net Loss

    Adjusted net loss is defined as GAAP net loss plus (i) amortization of intangible assets and (ii) additional infrequently occurring adjustments described in more detail below, less the estimated tax on these adjustments.

    The following table presents a reconciliation of GAAP net loss to non-GAAP adjusted net loss, for the periods presented:

      Three Months Ended March 31, 
      2025  2024 
      (Unaudited, in thousands) 
    Net loss $(18,843) $(2,100)
    Amortization of intangible assets  842   901 
    Write-down to fair value for asset held for sale1  6,567  — 
    Tax on above  (2,000)  (241)
    Adjusted net loss $(13,434) $(1,440)

    (1)   Amount reflects the fair value adjustment of a purchased building classified as held for sale.

    Non-GAAP Operating Loss

    Non-GAAP operating loss is defined as GAAP loss from operations plus (i) amortization of intangible assets and (ii) fair value adjustments related to a purchased building classified as held for sale.

    The following table presents a reconciliation of GAAP net loss from operations to non-GAAP operating loss, for the periods presented:

      Three Months Ended March 31, 
      2025  2024 
      (Unaudited, in thousands) 
    Loss from operations $(26,746) $(3,852)
    Amortization of intangible assets  842   901 
    Write-down to fair value for asset held for sale1  6,567  — 
    Non-GAAP operating loss $(19,337) $(2,951)

    (1)   Amount reflects the fair value adjustment of a purchased building classified as held for sale.

    Projected EBITDA and Adjusted EBITDA

    The following table presents a reconciliation of projected GAAP net income to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2025:

      Year Ended December 31, 
      2025L  2025H 
    Net income $4,700  $34,000 
    Interest income  (4,000)  (4,000)
    Income tax expense  1,400   11,700 
    Depreciation and amortization  14,600   14,600 
    Amortization of intangible assets  3,300   3,300 
    EBITDA $20,000  $59,600 
    Stock-based compensation expense  12,400   12,400 
    Write-down to fair value for asset held for sale1  6,600   6,600 
    FDA fee  4,600   4,600 
    Adjusted EBITDA $43,600  $83,200 

    (1)   Amount reflects the fair value adjustment of a purchased building classified as held for sale.

    Projected Adjusted Net Income

    The following table presents a reconciliation of projected GAAP net income to projected non-GAAP adjusted net income included in our guidance for the year ending December 31, 2025:

      Year Ending December 31, 
      2025L  2025H 
    Net income $4,700  $34,000 
    Amortization of intangible assets  3,300   3,300 
    Write-down to fair value for asset held for sale1  6,600   6,600 
    FDA fee  4,600   4,600 
    Tax on above  (3,900)  (3,900)
    Adjusted net income $15,300  $44,600 

    (1)   Amount reflects the fair value adjustment of a purchased building classified as held for sale.



    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company's expected revenue, net income, adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2025 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact and uncertainty of any changes to the coverage and reimbursement levels for the Company's products (including as a result of the proposed LCDs that could take effect as soon as January 1, 2026); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred losses in the current period and prior periods and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; (11) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA's enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; (12) whether the Company is able to obtain regulatory approval for and successfully commercialize ReNu; and (13) other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company's Form 10-K for the year ended December 31, 2024 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

    About Organogenesis Holdings Inc.

    Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.  



    Investor Inquiries:
    ICR Healthcare
    Mike Piccinino, CFA
    [email protected]
    443-213-0500
    
    Press and Media Inquiries:
    Organogenesis
    [email protected]

    Primary Logo

    Get the next $ORGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORGO

    DatePrice TargetRatingAnalyst
    6/28/2024$5.00Buy
    Lake Street
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    8/10/2022Outperform → Perform
    Oppenheimer
    11/10/2021$26.00 → $20.00Outperform
    SVB Leerink
    8/10/2021$24.00 → $25.00Outperform
    Credit Suisse
    More analyst ratings

    $ORGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Organogenesis with a new price target

      Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

      6/28/24 8:20:16 AM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

      Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00

      2/7/24 6:56:39 AM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Organogenesis with a new price target

      Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00

      6/15/23 7:30:00 AM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGO
    Financials

    Live finance-specific insights

    See more
    • Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

      CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill

      5/8/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the telec

      4/7/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

      CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. Fourth Quarter 2024 Financial Results Summary: Net revenue of $126.7 million for the fourth quarter of 2024, an increase of $27.0 million compared to net revenue of $99.7 million for the fourth quarter of 2023. Net revenue for the fourth quarter of 2024 consists of: Net revenue from A

      2/27/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 271 shares, decreasing direct ownership by 0.14% to 189,525 units (SEC Form 4)

      4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

      3/12/25 4:29:29 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Driscoll Michael Joseph sold $127,535 worth of shares (25,000 units at $5.10), decreasing direct ownership by 13% to 166,879 units (SEC Form 4)

      4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

      3/6/25 9:08:33 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 667 shares, decreasing direct ownership by 0.35% to 189,796 units (SEC Form 4)

      4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

      3/4/25 5:01:25 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ORGO
    Leadership Updates

    Live Leadership Updates

    See more

    $ORGO
    SEC Filings

    See more

    $ORGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

      CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill

      5/8/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

      CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Medicaid Services' (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies. "Organogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implem

      4/11/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the telec

      4/7/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Expands Manufacturing Capacity to Support Future Growth

      CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a

      11/22/24 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

      CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the

      11/12/24 4:01:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

      Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

      7/3/23 6:00:00 AM ET
      $BNOX
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Organogenesis Holdings Inc.

      10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/8/25 4:11:48 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/8/25 4:07:25 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Organogenesis Holdings Inc.

      PRE 14A - Organogenesis Holdings Inc. (0001661181) (Filer)

      4/29/25 5:15:35 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Organogenesis Holdings Inc.

      SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

      11/19/24 4:05:57 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

      SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

      11/14/24 8:09:56 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

      SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

      11/14/24 3:35:42 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care